Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Elijah S Parmer"'
Autor:
Adam S. Kinne, Erik J. Tillman, Sanofar J. Abdeen, Derrick E. Johnson, Elijah S. Parmer, Jacob P. Hurst, Brittany de Temple, Sherri Rinker, Timothy P. Rolph, Ronald R. Bowsher
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 232:115402
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5205fa2b9bda41eabd25acfeab510cf0
https://doi.org/10.1016/j.jpba.2023.115402
https://doi.org/10.1016/j.jpba.2023.115402
Autor:
Adam S Kinne, Swarna S. Ramaswamy, Derrick E. Johnson, Jennifer A Thystrup, Elijah S Parmer, Erica Simmons, Ronald R. Bowsher, Sherri Rinker, Sanofar J. Abdeen
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Today the evaluation of unwanted immunogenicity is a key component in the clinical safety evaluation of new biotherapeutic drugs and macromolecular delivery strategies. However, the evolving structural complexity in contemporary biotherapeutics creat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0431999374709fec265c538f42e040b3
https://doi.org/10.1038/s41598-021-95055-x
https://doi.org/10.1038/s41598-021-95055-x
Autor:
Ronald R. Bowsher, Elijah S Parmer, Timothy P Rolph, Adam S Kinne, Jennifer A Thystrup, Erik J. Tillman, Sanofar J. Abdeen
Publikováno v:
Journal of the Endocrine Society
Efruxifermin (EFX) is a novel Fc-fusion analog of human fibroblast growth factor 21 (FGF21), currently in clinical development as a potential treatment for non-alcoholic steatohepatitis (NASH). Each molecule of EFX consists of two modified FGF21 mole
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93251cf4787bbfe48475eaded3302150
https://doi.org/10.1210/jendso/bvab048.585
https://doi.org/10.1210/jendso/bvab048.585